Kornimate/medical-research-clean huggingface dataset:
short term effect of smoking cessation on human metabolism

Conditions: Smoking Cessation; Metabolic Syndrome

Summary: investigating the short term smoking cessation on metabolism, examining of participant of smoking cessation workshops and former participants' file survey for metabolic aspects

objective: to examine metabolic aspects occurring during the first 6-12 months following smoking cessation in participants of smoking cessation workshops. design: a two armed study: prospective and retrospective. prospective: weight, bmi, waist circumference and waist: hip ratio were measured before, during and 6 months post cessation program. retrospective: blood test data for blood fasting glucose (bfg) and lipid profile from the year preceding the workshops and the year after them were analyzed from participants' files. smoking status was verified by phone conversation.

Eligibility criteria:
inclusion criteria: * volunteers who were recruited from the smoking cessation workshops of the meuhedet hmo (israeli health services) during 2016-2017. exclusion criteria: * candidates with benign tumors, bariatric surgeries, and endoscopic bariatric procedures before or during the study period were excluded
oral nsai versus paracetamol or placebo as a second line treatment for renal colics

Conditions: Renal Colic

Summary: outpatients treatment with nsai in renal colics has not been well investigated and there is no clear recommendations regarding this matter. the aim of this study is to determine if an oral nsai treatment is beneficial in patients discharged for the emergency departement after the first line treatment of a renal colic investigating the recurrence of pain, the reconsultation rates and the admissions.

renal colic (rc)are a frequent cause of consultation in the emergency departement (ed). they count for approximatively 20% of patients presenting to the ed with severe acute onset abdominal pain. the first line treatment of renal colics is based on nsai drugs associated with antalgics and is further investigated in the nsai vs morphine study (nct02156596). but there is no clear recommendations regarding the outpatient treatment of renal colics. oral nsai are still widely used as a second line medicine for this condition and variety of molecules were tried with no solid scientific arguments. piroxicam, a non-selective cox inhibitor drug appared to the oxicam class of nsai, is widely used to treat rheumatoid conditions and other inflammatory conditions and often prescribed in tunisia as a second line treatment of rc. in this study, we aimed to investigate the efficiency and safety of the use of oral nsai drugs (piroxicam) compared to paracetamol or placebo as a second line treatment of renal colics.

Eligibility criteria:
inclusion criteria: * over 18 years old * consenting to participate in the study * patients treated in the ed for rc * no contraindications of nsai treatment exclusion criteria: * patients excluded from the first phase of the study * contraindication of nsai treatment * patients non reachable by telephone call * patients that did not receive or use the treatment

Keywords: renal colic, piroxicam
impact of maternal-infant therapeutics on safety, mortality, and disability

Conditions: Gastroesophageal Reflux; Presumed Sepsis; Patent Ductus Arteriosus; Chronic Lung Disease; Neurodevelopmental Impairment

Summary: the purpose of this research is to address the comparative effectiveness and harm of the therapeutics frequently given to pregnant women and their young infants including antibiotics, tocolytic agents, non-steroidal anti-inflammatory drugs, h2 blockers, and steroids. our overall hypothesis is that the use of an existing electronic medical record with additional resources for precise data collection and 18 month follow up will successfully address current knowledge gaps in therapeutic effectiveness and relative therapeutic harm. we will use an existing electronic medical record into which detailed healthcare information is entered for over 100,000 newborns each year. these infants will comprise the "source cohort". nested within that database, we will prospectively enroll 10% of the population (10,000 newborns) as the follow-up cohort. the current electronic medical record for the source cohort does not capture therapeutic dosing with sufficient precision to conduct comparative effectiveness research sufficient to change medical practice. the proposed research will: 1) ensure accurate data collection through electronic monitoring and real-time quality assurance evaluation in the source cohort; and 2) conduct 18 months post-hospital follow-up for neurologic outcomes and disability for the follow-up cohort. we will complete assessments of neurologic outcomes and disability using an interactive web-based system, mail, telephone follow up, and in-person examination.


Eligibility criteria:
inclusion criteria: * admitted to the a pediatrix medical group nicu * \<=5 days of life * likely to follow-up at 18 months adjusted age exclusion criteria: * failure to consent

Keywords: therapeutics safety maternal neonatal
thulium fiber laser en-bloc resection vs conventional transurethral resection of non-muscle-invasive bladder cancer

Conditions: Bladder Cancer

Summary: ongoing efforts aim at overcoming the challenges of conventional transurethral resection of bladder tumor (turbt) such as the high recurrence rate, difficulty of pathologic interpretation and complications including wall injury. possible advantages may have en bloc resection of bladder tumor which was previously shown to be effective and safe technique. use of novel thulium-fiber laser may also provide additional safety and efficacy of the resection. objective. to prospective assess the safety and efficacy of thulium-fiber en bloc resection of bladder tumor (tm-fiber-erbt) compared to turbt.

en bloc resection of bladder tumor (erbt) was first employed by kawada t. et al. in 1997. the technique showed promising results in terms of safety and tumor staging. development of laser surgery and emergence of the holmium (ho:yag) and later thulium (tm:yag) lasers in the 1990s enabled laser erbt with subsequent studies demonstrating high efficacy and safety of the new techniques. ho:yag and tm:yag erbt have distinct advantages over conventional turbt such as the complete absence of the obturator nerve reflex and hence, lower risks of perforation or bleeding as well as a higher quality specimens for pathologic examination, due to lack of the cautery effect. recently, a new type of thulium laser was developed - that allows to decrease the penetration depth less than 0.15 mm, which is two times less than that of tm:yag. another advantage is the decreased carbonization compared to tm:yag due to better water absorption of laser energy. all these aspects make tm:yag a precise tool that may improve the resection quality resulting in better management. data on laser erbt of nmibc with tm:yag is limited and that on tm-fiber laser erbt is absent altogether. the investigators hypothesized that tm-fiber laser erbt would result in a lower probability of adverse events and better recurrence-free survival compared to conventional turbt.

Eligibility criteria:
inclusion criteria: • primary ta or t1 bladder cancer (nmibc) exclusion criteria: • pure carcinoma in situ
gastric sleeve-induced weight loss on shortness of breath in obesity

Conditions: Dyspnea; Quality of Life

Summary: most research to date on bariatric surgery outcomes has been about metabolic syndrome, a disorder very effectively treated by bariatric surgery. however, obesity is also associated with many other problems that have received much less attention. amongst the most troubling of these for patients is dyspnea. dyspnea results in substantial patient distress that can greatly reduce health-related quality of life. little is known about the relationship between dyspnea, weight loss, and bariatric surgery. dyspnea is a complex symptom that may lead to adaptive responses, such as the need to rest as a consequence of even minimal activity or seeking medical attention. the main outcome of the study will be measured using a new state-of-the-science validated hrqol measure, the patient reported outcome measuring information system for heart failure (promis+hf 27).

the main purpose of this prospective matched cohort study is to determine the feasibility for a future, novel large-scale study, clinical trial that will aim to determine how common dyspnea is in obese patients, how much dyspnea affects their quality-of-life, and how these parameters are affected by medically or surgically induced weight loss. our basic assumption is that dyspnea is more common than is commonly believed in obese patients and that it profoundly affects quality of life. our main hypothesis is that weight loss improves dyspnea and hrqol and that bariatric surgery induced weight loss is more effective than medical weight loss at improving dyspnea-related quality-of-life.

Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age. 2. all patients undergoing gastric sleeve resection for serious obesity at the ronald reagan medical center will be considered for enrollment in the experimental group. 3. english/spanish speakers. 4. the patients included will be with preserved cognition and a capacity to understand questionnaires. 5. written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: 1. serious cardiovascular disease, previous gastrointestinal surgery, psychological concerns (mental disorders and dementia), recently hospitalized, pulmonary diseases, renal failure, or history of malignancy. 2. undergoing procedures other than gastric sleeve resection or are having these operations after they have had other bariatric procedures. 3. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. -
treatment patterns and key healthcare resource use in acute myeloid leukemia (aml) with or without fms-like tyrosine kinase-3 (flt3) mutation study based on retrospective chart review

Conditions: Acute Myeloid Leukemia (AML)

Summary: the purpose of this study is to retrospectively evaluate the treatment patterns and aml-related key healthcare resource use among aml patients, stratified by flt3 mutation status, intensive chemotherapy (ic) eligibility, and relapsed or refractory (r/r) status.

the current study is a retrospective non-interventional study using real-world data collected from existing medical records to evaluate descriptively the treatment patterns and key healthcare resource use among aml patients with or without flt3 mutation. the current study relies on secondary use of existing data, and there is no intervention involved. patients who received the first aml treatment after the initial diagnosis, or were classified as relapsed/refractory (r/r), between january 1, 2013 and december 31, 2015 will be randomly selected to be included in this study, and the data from their existing medical records will be extracted. eligible patients will be grouped based on flt3 mutation status, intensive chemotherapy (ic) eligibility, and r/r status. for newly diagnosed patients, the index date will be defined as the initiation date of the first aml treatment following initial diagnosis. for the r/r patients, the index date will be defined as the date of the patient being classified as r/r. the study period will be the period from the index date to last follow-up date or death, whichever comes earlier. the endpoint measurements of this study are treatment patterns and key aml-related healthcare resources used during the study period.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of aml but not acute promyelocytic leukemia (apl) * known flt3 mutation status * under the care of the participating physician during the past 3 years or from the initial diagnosis of aml * the medical records related to aml for the patient are available to the physician and can be abstracted for this study * the medical records contains complete information on treatments and aml-related hospitalization, including admission date, length of stay, and reason of hospitalization * initiation date of first treatment after aml diagnosis or date of being classified as relapsed from or being refractory to initial treatment (r/r) is between january 1, 2013 and december 31, 2015 exclusion criteria: * not applicable

Keywords: retrospective non-interventional study fms-like tyrosine kinase-3 (flt3) mutations
study of the prevalence of autistic traits in angelman syndrome

Conditions: Angelman Syndrome

Summary: the goal of this observational cross-sectional study is to establish the prevalence of autism spectrum disorder in children and adolescents with angelman syndrome. the main questions it aims to answer are: * which clinical variables differentiate as patients with and without autism spectrum disorder between genetics, epilepsy, pharmacotherapy, behavioural problems, parenting style and parents' perceived stress. * which clinical variables differentiate parenting styles and levels of perceived stress. data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("bayely scales of infant development-iii", cognitive scale) and adaptive behaviour; autism and autism spectrum disorder ("autism diagnostic observational schedule-2"); parental stress and parenting styles; social-communicative skills; motor development.


Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of angelman syndrome * chronological age between 4-15 years exclusion criteria: * genetic examination pending report * mental age lower than 12 months * brain injury acquired in the peri- or postnatal period
observe change of endotoxaemia and related mediators in patients with chronic hepatitis b virus (hbv) infection

Conditions: Hepatitis B, Chronic

Summary: this study was designed for changes in endotoxaemia, endotoxin-binding factors, sicam-1 (soluble intracellular adhesion molecule-1), and cytokines during progression of chronic hbv infection. patients with chronic hbv infection and healthy control are included. a limulus assay was used to measure plasma endotoxin level and elisas were used to measure the concentrations of interleukin-6 (il-6), interleukin-10 (il-10), tumor necrosis factor-α (tnfα), sicam-1, and soluble cd14 (scd14).

1. patients patients with chronic hbv infection and healthy volunteers were enrolled. there were asymptomatic carriers group, patients with chronic hepatitis, patients with hepatic cirrhosis, and patients with acute on chronic liver failure. 2. endotoxin assay blood samples were obtained under aseptic conditions by peripheral venipuncture and using pyrogen-free syringes, needles, and glassware. plasma samples were heated at 70℃ for 10 min. plasma concentration was then measured in duplicate using a commercially available limulus amebocyte lysate assay following the manufacturer's protocol. 3. elisa elisa kits were used to assess in duplicate the plasma concentrations of il-6, il-10, tnfα, sicam-1 and scd14.

Eligibility criteria:
inclusion criteria: * chronic hbv infection * diagnosis confirm to guideline of chronic hepatitis b and acute on chronic liver failure of the asian pacific association for the study of the liver (apasl). exclusion criteria: * all the patients had no obvious mycotic infection, gram-negative sepsis, or bacterial infection (except from the digestive system) * infection of hepatitis a, c, d, or e virus * autoimmune liver disease * alcoholic liver disease * metabolic liver disease * drug-induced liver injury * parasitic disease of the hepatobiliary system * malignancy * serious exacerbation of cardiovascular and respiratory system diseases

Keywords: endotoxaemia
cognitive impairment and upper extremity performance in copd

Conditions: COPD; Upper Extremity; Upper Limb Function; Cognitive Impairment

Summary: within the scope of this study, copd patients will be divided into two groups according to cognitive dysfunction. pulmonary function test, copd assessment scale, mini-mental state examination and montreal cognitive assessment scale, 6 min pegboard ring test, grip strength measurement, fatigue impact scale and st.george respiratory questionnaire will be applied to the groups.

although the mechanism of cognitive dysfunction in copd is not clear, the reasons focused on are; decreased oxygen use, high carbon dioxide levels, increased inflammation and oxidative stress, decreased physical activity, peripheral vascular diseases, atherosclerosis, high or low blood pressure, cerebral vasoconstriction, increased intracranial pressure, accompanying comorbidities, smoking and genetic predisposition, brain damage and exacerbations have been reported. few studies have shown that cognitive dysfunction is associated with functional performance. there are no studies on the effect of cognitive function on upper extremity performance and mechanisms of action in copd patients. the aim of this study is to compare upper extremity functional capacities, respiratory functions, fatigue and quality of life in copd patients with and without cognitive function impairment. within the scope of this study, copd patients will be divided into two groups according to cognitive dysfunction. pulmonary function test, copd assessment scale, mini-mental state examination and montreal cognitive assessment scale, 6 min pegboard ring test, grip strength measurement, fatigue impact scale and st.george respiratory questionnaire will be applied to the groups.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * stage 2-3-4 according to the gold classification in the 40-65 age range exclusion criteria: * exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness and/or sputum volume/color, need for antibiotic treatment or need for hospitalization) * presence of asthma, unstable coronary heart disease, uncontrolled diabetes, hypertension, left-sided congestive heart failure, neoplasia, severe claudication, encephalitis or epilepsy * having a history of head trauma or brain tumor * having a significant psychiatric condition or the presence of defined dementia, according to the american psychiatric association

Keywords: copd cognitive impairment cognition upper extremity
spastic cerebral palsy and slackline

Conditions: Spastic Cerebral Palsy

Summary: the aim of the present study was to assess whether supervised slackline training improves postural control in children and teenagers with spastic cerebral palsy (grade i and ii of the gross motor function classification system).


Eligibility criteria:
inclusion criteria: * diagnosis with any expression of spastic cerebral palsy and rated i-ii on the gross motor functional classification. * between 9 and 16 years of age. * ability to cooperate with simple instructions. * able to stand for at least 2 min without assistance. * able to walk at least 10 m without assistance. exclusion criteria: * individuals were excluded if they underwent neuro or orto surgery during or up to one year prior to the study, botulinum toxin injection or intrathecal pump during or up to six months prior to the study and/or rotational osteotomies, if they expressed gait deviations limited by musculoskeletal contracture, presented specific medical or orthopedic conditions that precluded exercising * or if they did not meet the eligibility criteria.
48-hour ambulatory eeg monitoring in early onset alzheimer's disease

Conditions: Early Onset Alzheimer Disease

Summary: researchers are trying to determine the frequency of seizures and epilepsy in patients with early-onset alzheimer's disease (eoad) using a 48-hour computer assisted ambulatory electroencephalogram.


Eligibility criteria:
inclusion criteria for eoad patients will be recruited from the leads trial with the following: * 40 to 64 years of age * meets nia-aa criteria for mild cognitive impairment (mci) due to ad or probable ad dementia. * have a global cdr score of ≤ 1.0 * have capacity to provide informed consent (icf) or has a legal authorized representative or guardian who provides ic. * amyloid positive status (pet scan with evidence of elevated amyloid) * must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, and caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. if the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the site pi. * not pregnant or lactating. women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each pet scan * fluent in english. exclusion criteria: * meets core clinical criteria for non-ad dementia. * two or more first degree relatives with a history of eoad suggestive of autosomal dominant transmission, unless known pathogenic mutations in app, psen1, psen2 have been excluded. * known mutation in an adad gene (app, psen1, psen2) or other autosomal dominant genes associated with other neurodegenerative disorders. * mri scans with evidence of infection or focal lesions, cortical strokes, multiple lacunes (single lacune is allowable unless it meets criteria for strategic lacune affecting cognition) * any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the site pi) * medical history of a brain disorder other than the disorder causing dementia except for headache. * deemed ineligible by the site pi for any other reason.